Compare McKesson Corporation (MCK) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs SkyWest Inc — how do they compare? McKesson Corporation trades at $828.8 (market cap $97.35B), while SkyWest Inc trades at $99.1 (market cap $3.94B). The key difference: McKesson Corporation is far larger — about 24.7× SkyWest Inc's market cap, and McKesson Corporation pays a 0.39% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| MCK | SKYW | |
|---|---|---|
Market Cap | $97.35B | $3.94B |
Sector | Health | Technology |
52-Week High | $995.69 | $123.72 |
52-Week Low | $659.01 | $78.40 |
Enterprise Value | $101.98B | $5.79B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
SkyWest (SKYW) trades at $99.34, up 2.17% today, with a neutral technical signal but bullish moving averages. The stock shows strong profitability with a 10.42% net margin and attractive valuation at a P/E of 9.32. Recent earnings have been mixed, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Analyst consensus is bullish with a $109.33 price target, though news highlights concerns over rising fuel costs impacting airline profits.
The outlook for SKYW is cautiously optimistic, supported by solid fundamentals and analyst buy ratings, but faces headwinds from volatile fuel expenses and competitive pressures. Upside potential exists if the company maintains earnings momentum and manages cost inflation, while downside risks include economic sensitivity and operational challenges in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
